NCT06928649 Stratifying Critically Ill Patients for Novel Ferroptosis or Pyroptosis Intervention Strategies
| NCT ID | NCT06928649 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University Hospital, Antwerp |
| Condition | Sepsis |
| Study Type | INTERVENTIONAL |
| Enrollment | 600 participants |
| Start Date | 2024-03-13 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 600 participants in total. It began in 2024-03-13 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In order to better determine which therapy is best for patiënts which present with organ falure during the course of their stay in the intesive care unit (ICU) , one has to determine which underlying mechanism is causing this organ falure. We will determine levels of so called "biomarkers" for ferroptosis (a mechan ism of iron-related cell death) in the peripheral blood and biological fluids of criticaly ill patients admitted to the ICU with a catastrrophy (severe infection, trauma ...) . Why ? If it turns out that this ferroptosis plays a role in the ocurrence of organ failure in the critially ill, this will lead to new therapies in the future as drugs become more and more available which can influene this biochemical "pahway". of iron-relatd death.
Eligibility Criteria
Inclusion Criteria: * Admitted to the ICU of UZA * Critically ill and predicted to be hospitalised in the ICU for \> 48 hours (i.e. mostly patients admitted for sepsis, trauma, haemorrhagic shock, neurological catastrophe … which means at risk to develop mono-or multiple organ failure) * With arterial line in place (for blood sampling) Exclusion Criteria: * Refusal of consent by patient or closest relative * Postoperative patients after major surgery in whom prolonged ICU stay is not foreseen (i.e. elective cardiac surgery
Contact & Investigator
Philippe Jorens, MD, PhD
PRINCIPAL INVESTIGATOR
University Hospital, Antwerp
Frequently Asked Questions
Who can join the NCT06928649 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Sepsis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06928649 currently recruiting?
Yes, NCT06928649 is actively recruiting participants. Contact the research team at tom.stroobants@uza.be for enrollment information.
Where is the NCT06928649 trial being conducted?
This trial is being conducted at Edegem, Belgium.
Who is sponsoring the NCT06928649 clinical trial?
NCT06928649 is sponsored by University Hospital, Antwerp. The principal investigator is Philippe Jorens, MD, PhD at University Hospital, Antwerp. The trial plans to enroll 600 participants.